{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:19:08Z","timestamp":1784074748530,"version":"3.55.0"},"reference-count":197,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22277138"],"award-info":[{"award-number":["22277138"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81725020"],"award-info":[{"award-number":["81725020"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973175"],"award-info":[{"award-number":["81973175"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003591"],"award-info":[{"award-number":["82003591"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"publisher","award":["2019-01-07-00-07-E00073"],"award-info":[{"award-number":["2019-01-07-00-07-E00073"]}],"id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["20S11900400"],"award-info":[{"award-number":["20S11900400"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFA0509200"],"award-info":[{"award-number":["2020YFA0509200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.addr.2023.114819","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T01:59:28Z","timestamp":1680573568000},"page":"114819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Target- and prodrug-based design for fungal diseases and cancer-associated fungal infections"],"prefix":"10.1016","volume":"197","author":[{"given":"Na","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanzhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunquan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2023.114819_b0005","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1126\/science.1222236","article-title":"Tackling human fungal infections","volume":"336","author":"Brown","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.114819_b0010","doi-asserted-by":"crossref","first-page":"165rv113","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: human fungal infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2023.114819_b0015","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd.2017.46","article-title":"The antifungal pipeline: a reality check","volume":"16","author":"Perfect","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2023.114819_b0020","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1126\/science.aaa6097","article-title":"How to bolster the antifungal pipeline","volume":"347","author":"Denning","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.114819_b0025","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1016\/j.cell.2022.09.005","article-title":"Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions","volume":"185","author":"Narunsky-Haziza","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.addr.2023.114819_b0030","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aap7999","article-title":"Worldwide emergence of resistance to antifungal drugs challenges human health and food security","volume":"360","author":"Fisher","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.114819_b0035","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41579-019-0322-2","article-title":"Drug resistance and tolerance in fungi","volume":"18","author":"Berman","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.addr.2023.114819_b0040","doi-asserted-by":"crossref","first-page":"680382","DOI":"10.3389\/fmicb.2021.680382","article-title":"Effects of Hsp90 inhibitor ganetespib on inhibition of azole-resistant Candida albicans","volume":"12","author":"Yuan","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2023.114819_b0045","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1130-1406(05)70048-6","article-title":"Genomics, molecular targets and the discovery of antifungal drugs","volume":"22","author":"Odds","year":"2005","journal-title":"Rev. Iberoam. Micol."},{"key":"10.1016\/j.addr.2023.114819_b0050","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.mib.2018.02.005","article-title":"Antifungal drug resistance: evolution, mechanisms and impact","volume":"45","author":"Revie","year":"2018","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.addr.2023.114819_b0055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10156-007-0595-7","article-title":"Current challenges in the management of invasive fungal infections","volume":"14","author":"Lai","year":"2008","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.addr.2023.114819_b0060","doi-asserted-by":"crossref","first-page":"e1004668","DOI":"10.1371\/journal.ppat.1004668","article-title":"Coping with stress and the emergence of multidrug resistance in fungi","volume":"11","author":"Shor","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.addr.2023.114819_b0065","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.mib.2013.03.005","article-title":"The fungal Achilles' heel: targeting Hsp90 to cripple fungal pathogens","volume":"16","author":"Cowen","year":"2013","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.addr.2023.114819_b0070","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41467-018-08248-w","article-title":"Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus","volume":"10","author":"Whitesell","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2023.114819_b0075","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.fbr.2014.02.004","article-title":"Calcineurin as a multifunctional regulator: Unraveling novel functions in fungal stress responses, hyphal growth, drug resistance, and pathogenesis","volume":"28","author":"Juvvadi","year":"2014","journal-title":"Fungal Biol. Rev."},{"key":"10.1016\/j.addr.2023.114819_b0080","doi-asserted-by":"crossref","unstructured":"Y.L. Chen, J.H. Konieczka, D.J. Springer, S.E. Bowen, J. Zhang, F.G.S. Silao, A.A.C. Bungay, U.G. Bigol, M.G. Nicolas, S.N. Abraham, Convergent evolution of calcineurin pathway roles in thermotolerance and virulence in Candida glabrata, G3 (Bethesda) 2 (2012) 675-691.","DOI":"10.1534\/g3.112.002279"},{"key":"10.1016\/j.addr.2023.114819_b0085","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1128\/EC.00310-10","article-title":"Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis","volume":"10","author":"Chen","year":"2011","journal-title":"Eukaryotic Cell"},{"key":"10.1016\/j.addr.2023.114819_b0090","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12281-010-0027-5","article-title":"On the roles of calcineurin in fungal growth and pathogenesis","volume":"4","author":"Chen","year":"2010","journal-title":"Curr. Fungal Infect. Rep."},{"key":"10.1016\/j.addr.2023.114819_b0095","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1126\/science.1118370","article-title":"Hsp90 potentiates the rapid evolution of new traits: Drug resistance in diverse fungi","volume":"309","author":"Cowen","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.114819_b0100","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1073\/pnas.0813394106","article-title":"Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease","volume":"106","author":"Cowen","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2023.114819_b0105","doi-asserted-by":"crossref","unstructured":"Cowen, Leah, E., Hsp90 orchestrates stress response signaling governing fungal drug resistance, PLoS Pathog.. 5 (2009) e1000471.","DOI":"10.1371\/journal.ppat.1000471"},{"key":"10.1016\/j.addr.2023.114819_b0110","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.celrep.2012.08.035","article-title":"Lysine deacetylases Hda1 and Rpd3 regulate Hsp90 function thereby governing fungal drug resistance","volume":"2","author":"Robbins","year":"2012","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2023.114819_b0115","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrmicro2875","article-title":"Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs","volume":"10","author":"Leach","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.addr.2023.114819_b0120","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.tim.2017.05.003","article-title":"The Hsp90 chaperone network modulates Candida virulence traits","volume":"25","author":"O'Meara","year":"2017","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.addr.2023.114819_b0125","first-page":"310","article-title":"Heat shock protein 90 (Hsp90): A novel antifungal target against Aspergillus fumigatus","volume":"42","author":"Lamoth","year":"2014","journal-title":"Crit. Rev. Microbiol."},{"key":"10.1016\/j.addr.2023.114819_b0130","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3892\/or.2022.8443","article-title":"HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)","volume":"49","author":"Li","year":"2023","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.addr.2023.114819_b0135","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1128\/AAC.01857-12","article-title":"In vitro activity of calcineurin and heat shock protein 90 inhibitors against Aspergillus fumigatus azole- and echinocandin-resistant strains","volume":"57","author":"Lamoth","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2023.114819_b0140","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3389\/fmicb.2015.01241","article-title":"Heat shock protein 90 (Hsp90) as a molecular target for the development of novel drugs against the dermatophyte trichophyton rubrum","volume":"6","author":"Jacob","year":"2015","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2023.114819_b0145","first-page":"2589","article-title":"The non-Geldanamycin Hsp90 inhibitors enhanced the antifungal activity of fluconazole","volume":"7","author":"Liping Li","year":"2015","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.addr.2023.114819_b0150","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1021\/acs.jmedchem.9b00826","article-title":"Design and synthesis of fungal-selective resorcylate aminopyrazole Hsp90 inhibitors","volume":"63","author":"Huang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0155","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1021\/acs.jmedchem.0c01777","article-title":"Fungal-selective resorcylate aminopyrazole Hsp90 inhibitors: Optimization of whole-cell anticryptococcal activity and insights into the structural origins of cryptococcal selectivity","volume":"64","author":"Marcyk","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0160","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1021\/acs.jmedchem.1c01991","article-title":"Species-selective targeting of fungal Hsp90: Design, synthesis, and evaluation of novel 4,5-Diarylisoxazole derivatives for the combination treatment of azole-resistant candidiasis","volume":"65","author":"Yin","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0165","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3389\/fmicb.2016.01238","article-title":"Histone deacetylases and their inhibition in Candida species","volume":"7","author":"Garnaud","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2023.114819_b0170","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2217\/fmb-2019-0343","article-title":"Histone acetylation\/deacetylation in Candida albicans and their potential as antifungal targets","volume":"15","author":"Su","year":"2020","journal-title":"Future Microbiol."},{"key":"10.1016\/j.addr.2023.114819_b0175","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1128\/AAC.46.11.3532-3539.2002","article-title":"Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation","volume":"46","author":"Smith","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2023.114819_b0180","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.bmcl.2006.12.028","article-title":"Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans","volume":"17","author":"Mai","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.addr.2023.114819_b0185","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/jac\/dkv070","article-title":"The Rpd3\/Hda1 family of histone deacetylases regulates azole resistance in Candida albicans","volume":"70","author":"Li","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2023.114819_b0190","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1128\/JCM.00618-09","article-title":"Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens","volume":"47","author":"Pfaller","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.addr.2023.114819_b0195","first-page":"505","article-title":"Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed, Future","volume":"4","author":"Gryder","year":"2012","journal-title":"Med. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0200","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1021\/acs.jmedchem.0c01763","article-title":"Novel carboline fungal histone deacetylase (HDAC) inhibitors for combinational treatment of azole-resistant candidiasis","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0205","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1365-2958.2011.07632.x","article-title":"SEC14 is a specific requirement for secretion of phospholipase B1 and pathogenicity of Cryptococcus neoformans","volume":"80","author":"Chayakulkeeree","year":"2011","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.addr.2023.114819_b0210","doi-asserted-by":"crossref","first-page":"6754","DOI":"10.3390\/ijms22136754","article-title":"Emerging prospects for combating fungal infections by targeting phosphatidylinositol transfer proteins","volume":"22","author":"Khan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2023.114819_b0215","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.abd6919","article-title":"A marine microbiome antifungal targets urgent-threat drug-resistant fungi","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.114819_b0220","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/nchembio.2165","article-title":"Dual action antifungal small molecule modulates multidrug efflux and TOR signaling","volume":"12","author":"Shekhar-Guturja","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.addr.2023.114819_b0225","doi-asserted-by":"crossref","first-page":"e1001069","DOI":"10.1371\/journal.ppat.1001069","article-title":"PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90","volume":"6","author":"LaFayette","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.addr.2023.114819_b0230","first-page":"269","article-title":"Overcoming fungal echinocandin resistance through inhibition of the non-essential stress kinase Yck2, Cell","volume":"27","author":"Caplan","year":"2020","journal-title":"Chem. Biol."},{"key":"10.1016\/j.addr.2023.114819_b0235","doi-asserted-by":"crossref","first-page":"e3000104","DOI":"10.1371\/journal.pbio.3000104","article-title":"Spliceosomal Prp8 intein at the crossroads of protein and RNA splicing","volume":"17","author":"Green","year":"2019","journal-title":"PLoS Biol."},{"key":"10.1016\/j.addr.2023.114819_b0240","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/22221751.2019.1625727","article-title":"Cisplatin protects mice from challenge of Cryptococcus neoformans by targeting the Prp8 intein, Emerg","volume":"8","author":"Li","year":"2019","journal-title":"Microbes Infect."},{"key":"10.1016\/j.addr.2023.114819_b0245","doi-asserted-by":"crossref","first-page":"22661","DOI":"10.1074\/jbc.M116.747824","article-title":"Exploring intein inhibition by platinum compounds as an antimicrobial strategy","volume":"291","author":"Chan","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0250","article-title":"Small-molecule inhibitors for the Prp8 intein as antifungal agents","volume":"118","author":"Li","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2023.114819_b0255","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1089\/ars.2012.5033","article-title":"Functions and cellular compartmentation of the thioredoxin and glutathione pathways in yeast","volume":"18","author":"Toledano","year":"2013","journal-title":"Antioxid. Redox Signaling"},{"key":"10.1016\/j.addr.2023.114819_b0260","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1046\/j.1432-1327.2000.01701.x","article-title":"Physiological functions of thioredoxin and thioredoxin reductase","volume":"267","author":"Arn\u00e9r","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.addr.2023.114819_b0265","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.freeradbiomed.2013.07.036","article-title":"The thioredoxin antioxidant system","volume":"66","author":"Lu","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.addr.2023.114819_b0270","doi-asserted-by":"crossref","first-page":"693","DOI":"10.15252\/embj.201695336","article-title":"Cytosolic thioredoxin reductase 1 is required for correct disulfide formation in the ER","volume":"36","author":"Poet","year":"2017","journal-title":"EMBO J."},{"key":"10.1016\/j.addr.2023.114819_b0275","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1021\/bi901962p","article-title":"Insights into the specificity of thioredoxin reductase-thioredoxin interactions. A structural and functional investigation of the yeast thioredoxin system","volume":"49","author":"Oliveira","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.addr.2023.114819_b0280","doi-asserted-by":"crossref","first-page":"9533","DOI":"10.1073\/pnas.171178698","article-title":"Three-dimensional structure of a mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteine-dependent enzyme","volume":"98","author":"Sandalova","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2023.114819_b0285","doi-asserted-by":"crossref","first-page":"17045","DOI":"10.1074\/jbc.272.27.17045","article-title":"Thioredoxin reductase-dependent inhibition of MCB cell cycle box activity in Saccharomyces cerevisiae","volume":"272","author":"Machado","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0290","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1371\/journal.ppat.0030024","article-title":"Essential gene identification and drug target prioritization in Aspergillus fumigatus","volume":"3","author":"Hu","year":"2007","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.addr.2023.114819_b0295","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/npp.2015.343","article-title":"Effect of the putative lithium mimetic ebselen on brain myo-inositol, sleep, and emotional processing in humans","volume":"41","author":"Singh","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.addr.2023.114819_b0300","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0140-6736(17)31791-9","article-title":"Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"390","author":"Kil","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2023.114819_b0305","doi-asserted-by":"crossref","first-page":"e0133877","DOI":"10.1371\/journal.pone.0133877","article-title":"Repurposing clinical molecule ebselen to combat drug resistant pathogens","volume":"10","author":"Thangamani","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2023.114819_b0310","first-page":"3002","article-title":"Ebselen exerts antifungal activity by regulating glutathione (GSH) and reactive oxygen species (ROS) production in fungal cells","volume":"2017","author":"Thangamani","year":"1861","journal-title":"Biochim. Biophys. Acta. Gen. Subj."},{"key":"10.1016\/j.addr.2023.114819_b0315","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1096\/fj.12-223305","article-title":"Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione","volume":"27","author":"Lu","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.addr.2023.114819_b0320","doi-asserted-by":"crossref","first-page":"e02281","DOI":"10.1128\/AAC.02281-18","article-title":"Structure, mechanism, and inhibition of Aspergillus fumigatus thioredoxin reductase","volume":"63","author":"Marshall","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2023.114819_b0325","doi-asserted-by":"crossref","first-page":"e00765","DOI":"10.1128\/mBio.00765-13","article-title":"Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo","volume":"5","author":"Butts","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.addr.2023.114819_b0330","doi-asserted-by":"crossref","first-page":"e01126","DOI":"10.1128\/mBio.01126-14","article-title":"The triphenylethylenes, a novel class of antifungals","volume":"5","author":"Odom","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.addr.2023.114819_b0335","doi-asserted-by":"crossref","first-page":"e00079","DOI":"10.1128\/AAC.00079-20","article-title":"NADPH-Cytochrome P450 reductase Ccr1 is a target of tamoxifen and participates in its antifungal activity via regulating cell wall integrity in fission yeast","volume":"64","author":"Liu","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2023.114819_b0340","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1128\/EC.05138-11","article-title":"Cell wall chitosan is necessary for virulence in the opportunistic pathogen Cryptococcus neoformans","volume":"10","author":"Baker","year":"2011","journal-title":"Eukaryotic Cell"},{"key":"10.1016\/j.addr.2023.114819_b0345","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1128\/EC.00399-06","article-title":"Chitosan, the deacetylated form of chitin, is necessary for cell wall integrity in Cryptococcus neoformans","volume":"6","author":"Baker","year":"2007","journal-title":"Eukaryotic Cell"},{"key":"10.1016\/j.addr.2023.114819_b0350","doi-asserted-by":"crossref","first-page":"e02264","DOI":"10.1128\/mBio.02264-19","article-title":"The aminoalkylindole BML-190 negatively regulates chitosan synthesis via the cyclic AMP\/protein kinase A1 pathway in Cryptococcus neoformans","volume":"10","author":"Maybruck","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.addr.2023.114819_b0355","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0014-5793(03)00048-6","article-title":"BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates","volume":"536","author":"New","year":"2003","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2023.114819_b0360","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1534\/genetics.111.133363","article-title":"Target of rapamycin (TOR) in nutrient signaling and growth control","volume":"189","author":"Loewith","year":"2011","journal-title":"Genetics"},{"key":"10.1016\/j.addr.2023.114819_b0365","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1091\/mbc.12.12.4103","article-title":"The TOR signal transduction cascade controls cellular differentiation in response to nutrients","volume":"12","author":"Cutler","year":"2001","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.addr.2023.114819_b0370","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1128\/EC.00165-09","article-title":"Transcriptional responses of Candida albicans to epithelial and endothelial cells","volume":"8","author":"Park","year":"2009","journal-title":"Eukaryotic Cell"},{"key":"10.1016\/j.addr.2023.114819_b0375","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1128\/AAC.45.11.3162-3170.2001","article-title":"Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR","volume":"45","author":"Cruz","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2023.114819_b0380","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.1073\/pnas.1617799114","article-title":"Phosphate is the third nutrient monitored by TOR in Candida albicans and provides a target for fungal-specific indirect TOR inhibition","volume":"114","author":"Liu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2023.114819_b0385","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/EC.05184-11","article-title":"Mitochondria and fungal pathogenesis: drug tolerance, virulence, and potential for antifungal therapy","volume":"10","author":"Shingu-Vazquez","year":"2011","journal-title":"Eukaryotic Cell"},{"key":"10.1016\/j.addr.2023.114819_b0390","doi-asserted-by":"crossref","first-page":"e1005133","DOI":"10.1371\/journal.ppat.1005133","article-title":"Mitochondrial activity and Cyr1 are key regulators of Ras1 activation of C. albicans virulence pathways","volume":"11","author":"Grahl","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.addr.2023.114819_b0395","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nchembio.2534","article-title":"Inhibiting mitochondrial phosphate transport as an unexploited antifungal strategy","volume":"14","author":"McLellan","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.addr.2023.114819_b0400","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1021\/cb300235m","article-title":"Inhibiting GPI anchor biosynthesis in fungi stresses the endoplasmic reticulum and enhances immunogenicity","volume":"7","author":"McLellan","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.addr.2023.114819_b0405","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.00731-11","article-title":"E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis","volume":"56","author":"Watanabe","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2023.114819_b0410","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1128\/jb.179.7.2202-2209.1997","article-title":"Restrictive glycosylphosphatidylinositol anchor synthesis in cwh6\/gpi3 yeast cells causes aberrant biogenesis of cell wall proteins","volume":"179","author":"Vossen","year":"1997","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.addr.2023.114819_b0415","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1046\/j.1365-2958.2003.03481.x","article-title":"Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly","volume":"48","author":"Tsukahara","year":"2003","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.addr.2023.114819_b0420","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1021\/id5000212","article-title":"Chemical genomics-based antifungal drug discovery: Targeting glycosylphosphatidylinositol (GPI) precursor biosynthesis","volume":"1","author":"Mann","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.addr.2023.114819_b0425","doi-asserted-by":"crossref","first-page":"35099","DOI":"10.1074\/jbc.274.49.35099","article-title":"Pig-n, a mammalian homologue of yeast Mcd4p, is involved in transferring phosphoethanolamine to the first mannose of the glycosylphosphatidylinositol","volume":"274","author":"Hong","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0430","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1038\/s41467-020-17221-5","article-title":"Jawsamycin exhibits in vivo antifungal properties by inhibiting Spt14\/Gpi3-mediated biosynthesis of glycosylphosphatidylinositol","volume":"11","author":"Fu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2023.114819_b0435","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1080\/21505594.2015.1039885","article-title":"Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans","volume":"6","author":"Cui","year":"2015","journal-title":"Virulence"},{"key":"10.1016\/j.addr.2023.114819_b0440","doi-asserted-by":"crossref","first-page":"e01991","DOI":"10.1128\/mBio.01991-17","article-title":"Development of anti-virulence approaches for candidiasis via a novel series of small-molecule inhibitors of Candida albicans filamentation","volume":"8","author":"Romo","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.addr.2023.114819_b0445","first-page":"1795","article-title":"The arsenal of pathogens and antivirulence therapeutic strategies for disarming them","volume":"10","author":"Brannon","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.addr.2023.114819_b0450","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.mycres.2007.11.013","article-title":"An expanded family of fungalysin extracellular metallopeptidases of Coprinopsis cinerea","volume":"112","author":"Lilly","year":"2008","journal-title":"Mycol. Res."},{"key":"10.1016\/j.addr.2023.114819_b0455","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1107\/S0907444913017642","article-title":"A functional and structural study of the major metalloprotease secreted by the pathogenic fungus Aspergillus fumigatus, Acta Crystallogr","volume":"69","author":"Fern\u00e1ndez","year":"2013","journal-title":"Sect. D: Biol. Crystallogr."},{"key":"10.1016\/j.addr.2023.114819_b0460","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/s41467-020-15329-2","article-title":"Fungal kinases and transcription factors regulating brain infection in Cryptococcus neoformans","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2023.114819_b0465","doi-asserted-by":"crossref","first-page":"e01101","DOI":"10.1128\/mBio.01101-14","article-title":"Invasion of the central nervous system by Cryptococcus neoformans requires a secreted fungal metalloprotease","volume":"5","author":"Vu","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.addr.2023.114819_b0470","doi-asserted-by":"crossref","first-page":"e0203020","DOI":"10.1371\/journal.pone.0203020","article-title":"The structure-function analysis of the Mpr1 metalloprotease determinants of activity during migration of fungal cells across the blood-brain barrier","volume":"13","author":"Na Pombejra","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2023.114819_b0475","doi-asserted-by":"crossref","first-page":"e01249","DOI":"10.1128\/mBio.01249-20","article-title":"An antivirulence approach for preventing Cryptococcus neoformans from crossing the blood-brain barrier via novel natural product inhibitors of a fungal metalloprotease","volume":"11","author":"Aaron","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.addr.2023.114819_b0480","first-page":"47","article-title":"Use of antifungal combination therapy","volume":"46","author":"Perez Diaz","year":"2010","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.addr.2023.114819_b0485","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.4014\/jmb.1807.07002","article-title":"Novel approaches for efficient antifungal drug action","volume":"28","author":"Lee","year":"2018","journal-title":"J. Microbiol. Biotechnol."},{"key":"10.1016\/j.addr.2023.114819_b0490","doi-asserted-by":"crossref","first-page":"759408","DOI":"10.3389\/fcimb.2021.759408","article-title":"Drug resistance and novel therapeutic approaches in invasive candidiasis","volume":"11","author":"Murphy","year":"2021","journal-title":"Front. Cell Infect. Microbiol."},{"key":"10.1016\/j.addr.2023.114819_b0495","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/acs.jmedchem.8b00760","article-title":"Polypharmacology by design: A medicinal chemist's perspective on multitargeting compounds","volume":"62","author":"Proschak","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0500","doi-asserted-by":"crossref","first-page":"106055","DOI":"10.1016\/j.phrs.2021.106055","article-title":"Polypharmacology: The science of multi-targeting molecules","volume":"176","author":"Kabir","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.addr.2023.114819_b0505","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/21505594.2016.1196300","article-title":"Combinatorial strategies for combating invasive fungal infections","volume":"8","author":"Spitzer","year":"2017","journal-title":"Virulence"},{"key":"10.1016\/j.addr.2023.114819_b0510","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejmech.2017.05.016","article-title":"Designing multi-targeted agents: An emerging anticancer drug discovery paradigm","volume":"136","author":"Fu","year":"2017","journal-title":"Eur J. Med. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0515","doi-asserted-by":"crossref","first-page":"8881","DOI":"10.1021\/acs.jmedchem.9b00017","article-title":"Rational design of multitarget-directed ligands: Strategies and emerging paradigms","volume":"62","author":"Zhou","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0520","doi-asserted-by":"crossref","unstructured":"V.V. Kleandrova, L. Scotti, F.J. Bezerra Mendon\u00e7a Junior, E. Muratov, M.T. Scotti, A. Speck-Planche, QSAR modeling for multi-target drug discovery: Designing simultaneous inhibitors of proteins in diverse pathogenic parasites, Front. Chem. 9 (2021) 634663-634672.","DOI":"10.3389\/fchem.2021.634663"},{"key":"10.1016\/j.addr.2023.114819_b0525","first-page":"1801","article-title":"Multi-Target QSAR approaches for modeling protein inhibitors. Simultaneous prediction of activities against biomacromolecules present in gram-negative bacteria, Curr. Top","volume":"15","author":"Speck-Planche","year":"2015","journal-title":"Med. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0530","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed multiple ligands. An emerging drug discovery paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0535","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3390\/genes12101470","article-title":"Fungal lysine deacetylases in virulence, resistance, and production of small bioactive compounds","volume":"12","author":"Bauer","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.addr.2023.114819_b0540","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1021\/acs.jmedchem.0c00102","article-title":"Discovery of novel fungal lanosterol 14\u03b1-demethylase (CYP51)\/histone deacetylase dual inhibitors to treat azole-resistant candidiasis","volume":"63","author":"Han","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0545","doi-asserted-by":"crossref","first-page":"113524","DOI":"10.1016\/j.ejmech.2021.113524","article-title":"Lanosterol 14\u03b1-demethylase (CYP51)\/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections","volume":"221","author":"Zhu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0550","doi-asserted-by":"crossref","first-page":"113961","DOI":"10.1016\/j.ejmech.2021.113961","article-title":"Heat shock protein 90 (Hsp90)\/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans","volume":"227","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0555","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1517\/13543776.2015.1090973","article-title":"COX inhibitors: a patent review (2011\u20132014)","volume":"25","author":"Consalvi","year":"2015","journal-title":"Expert. Opin. Ther. Pat."},{"key":"10.1016\/j.addr.2023.114819_b0560","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bjid.2013.09.006","article-title":"Arachidonic acid affects biofilm formation and PGE2 level in Candida albicans and non-albicans species in presence of subinhibitory concentration of fluconazole and terbinafine","volume":"18","author":"Mishra","year":"2014","journal-title":"Braz. J. Infect. Dis."},{"key":"10.1016\/j.addr.2023.114819_b0565","doi-asserted-by":"crossref","first-page":"e02268","DOI":"10.1128\/AAC.02268-16","article-title":"Antimicrobial effects of antipyretics","volume":"61","author":"Zimmermann","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2023.114819_b0570","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1567-1364.2009.00504.x","article-title":"Ibuprofen reverts antifungal resistance on Candida albicans showing overexpression of CDR genes","volume":"9","author":"Ricardo","year":"2009","journal-title":"FEMS Yeast Res."},{"key":"10.1016\/j.addr.2023.114819_b0575","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1021\/acs.jmedchem.1c01807","article-title":"Fluconazole-COX inhibitor hybrids: A dual-acting class of antifungal azoles","volume":"65","author":"Elias","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0580","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1021\/ci100403b","article-title":"Detailed mechanism of squalene epoxidase inhibition by terbinafine","volume":"51","author":"Nowosielski","year":"2011","journal-title":"J. Chem. Inf. Model"},{"key":"10.1016\/j.addr.2023.114819_b0585","doi-asserted-by":"crossref","first-page":"6728","DOI":"10.1074\/jbc.M117.778308","article-title":"Structural analyses of Candida albicans sterol 14\u03b1-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis","volume":"292","author":"Hargrove","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112645","article-title":"Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors","volume":"205","author":"Sun","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0595","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/myc.12081","article-title":"Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study","volume":"56","author":"Lewis","year":"2013","journal-title":"Mycoses"},{"key":"10.1016\/j.addr.2023.114819_b0600","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1086\/522189","article-title":"Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study\u2013Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne","volume":"45","author":"Pagano","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2023.114819_b0605","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2023.114819_b0610","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.21723","article-title":"Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2023.114819_b0615","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/2040620711410098","article-title":"Invasive fungal infections in acute leukemia","volume":"2","author":"Bhatt","year":"2011","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.addr.2023.114819_b0620","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/cid\/civ293","article-title":"Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031)","volume":"61","author":"Cornely","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2023.114819_b0625","doi-asserted-by":"crossref","unstructured":"M.Z. Gomes, V.E. Mulanovich, Y. Jiang, R.E. Lewis, D.P. Kontoyiannis, Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011, Antimicrob. Agents Chemother. 58 (2014) 865-873.","DOI":"10.1128\/AAC.01525-13"},{"key":"10.1016\/j.addr.2023.114819_b0630","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/myc.12500","article-title":"Invasive fungal infections in AML\/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?","volume":"59","author":"Pomares","year":"2016","journal-title":"Mycoses"},{"key":"10.1016\/j.addr.2023.114819_b0635","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ajh.25808","article-title":"Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents","volume":"95","author":"Kim","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.addr.2023.114819_b0640","doi-asserted-by":"crossref","first-page":"e2018063","DOI":"10.4084\/mjhid.2018.063","article-title":"Invasive fungal infections in patients with chronic lymphoproliferative disorders in the Era of target drugs","volume":"10","author":"Facchinelli","year":"2018","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"10.1016\/j.addr.2023.114819_b0645","doi-asserted-by":"crossref","unstructured":"J.A. Maertens, C. Girmenia, R.J. Br\u00fcggemann, R.F. Duarte, C.C. Kibbler, P. Ljungman, Z. Racil, P. Ribaud, M.A. Slavin, O.A. Cornely, J. Peter Donnelly, C. Cordonnier, European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia, J. Antimicrob. Chemother. 73 (2018) 3221-3230.","DOI":"10.1093\/jac\/dky286"},{"key":"10.1016\/j.addr.2023.114819_b0650","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/pathogens5010006","article-title":"How Chemotherapy increases the risk of systemic candidiasis in cancer patients: Current paradigm and future directions","volume":"5","author":"Teoh","year":"2016","journal-title":"Pathogens"},{"key":"10.1016\/j.addr.2023.114819_b0655","doi-asserted-by":"crossref","first-page":"4.5.19","DOI":"10.1128\/microbiolspec.FUNK-0002-2016","article-title":"Antifungal drugs: The current armamentarium and development of new agents","volume":"4","author":"Robbins","year":"2016","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.addr.2023.114819_b0660","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.mycmed.2018.10.006","article-title":"Systemic infection with Candida albicans in breast tumor bearing mice: Cytokines dysregulation and induction of regulatory T cells","volume":"29","author":"Ahmadi","year":"2019","journal-title":"J. Mycol. Med."},{"key":"10.1016\/j.addr.2023.114819_b0665","first-page":"81","article-title":"The effect of Candida albicans systemic infection on matrix metalloproteinases in breast cancer bearing BALB\/c mice, Iran","volume":"12","author":"Hajari Taheri","year":"2013","journal-title":"J. Allergy, Asthma Immunol."},{"key":"10.1016\/j.addr.2023.114819_b0670","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3892\/ol_00000039","article-title":"A comparative histopathological study of systemic candidiasis in association with experimentally induced breast cancer","volume":"1","author":"Choo","year":"2010","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.addr.2023.114819_b0675","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3390\/jof7121058","article-title":"Invasive fungal infections and targeted therapies in hematological malignancies","volume":"7","author":"Little","year":"2021","journal-title":"J. Fungi (Basel)"},{"key":"10.1016\/j.addr.2023.114819_b0680","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nri1226","article-title":"Regulation of JAK-STAT signalling in the immune system","volume":"3","author":"Shuai","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2023.114819_b0685","doi-asserted-by":"crossref","first-page":"114760","DOI":"10.1016\/j.bcp.2021.114760","article-title":"Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential","volume":"193","author":"Tzeng","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.addr.2023.114819_b0690","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.clinthera.2014.06.018","article-title":"Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis","volume":"36","author":"Kaur","year":"2014","journal-title":"Clin. Ther."},{"key":"10.1016\/j.addr.2023.114819_b0695","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.2165\/11209340-000000000-00000","article-title":"Ruxolitinib: in the treatment of myelofibrosis","volume":"72","author":"Yang","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2023.114819_b0700","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1158\/1078-0432.CCR-13-0279","article-title":"Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors","volume":"20","author":"Meyer","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2023.114819_b0705","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1182\/blood-2009-05-222133","article-title":"Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.addr.2023.114819_b0710","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1158\/1078-0432.CCR-13-0905","article-title":"JAK1\/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease","volume":"19","author":"Evrot","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2023.114819_b0715","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1038\/bcj.2012.14","article-title":"The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML","volume":"2","author":"Novotny-Diermayr","year":"2012","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.addr.2023.114819_b0720","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1021\/acs.jmedchem.8b00393","article-title":"Discovery of janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors as a novel strategy for the combinational treatment of leukemia and invasive fungal infections","volume":"61","author":"Huang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0725","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0014-5793(01)03309-9","article-title":"Bromodomain: an acetyl-lysine binding domain","volume":"513","author":"Zeng","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2023.114819_b0730","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: epigenetic readers of lysine acetylation","volume":"13","author":"Filippakopoulos","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2023.114819_b0735","first-page":"B1","article-title":"Brd4 engagement from chromatin targeting to transcriptional regulation: selective contact with acetylated histone H3 and H4, F1000 Biol","volume":"1","author":"Chiang","year":"2009","journal-title":"Rep."},{"key":"10.1016\/j.addr.2023.114819_b0740","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.114819_b0745","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1021\/acs.jmedchem.8b00483","article-title":"Structure-based discovery of CF53 as a potent and orally bioavailable bromodomain and extra-terminal (BET) bromodomain inhibitor","volume":"61","author":"Zhao","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0750","doi-asserted-by":"crossref","first-page":"A49","DOI":"10.1158\/1535-7163.TARG-15-A49","article-title":"Abstract A49: Clinically efficacy of the BET bromodomain inhibitor TEN-010 in an open-label substudy with patients with documented NUT-midline carcinoma (NMC)","volume":"14","author":"Shapiro","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.addr.2023.114819_b0755","doi-asserted-by":"crossref","first-page":"8369","DOI":"10.1021\/acs.jmedchem.7b00746","article-title":"Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075\/Mivebresib), a potent and orally available bromodomain and extraterminal domain (BET) family bromodomain inhibitor","volume":"60","author":"McDaniel","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0760","doi-asserted-by":"crossref","first-page":"19754","DOI":"10.1073\/pnas.1310658110","article-title":"RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain","volume":"110","author":"Picaud","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2023.114819_b0765","doi-asserted-by":"crossref","first-page":"15482","DOI":"10.1038\/ncomms15482","article-title":"Selective BET bromodomain inhibition as an antifungal therapeutic strategy","volume":"8","author":"Mietton","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2023.114819_b0770","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.2c01191","article-title":"BET-HDAC dual inhibitors for combinational treatment of breast cancer and concurrent candidiasis","author":"Huang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2023.114819_b0775","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrd.2018.46","article-title":"The expanding role of prodrugs in contemporary drug design and development","volume":"17","author":"Rautio","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2023.114819_b0780","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejps.2017.08.002","article-title":"Prodrugs - Recent approvals and a glimpse of the pipeline","volume":"109","author":"Rautio","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.114819_b0785","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ijpp.12302","article-title":"Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections","volume":"25","author":"Murrell","year":"2017","journal-title":"Int. J. Pharm. Pract."},{"key":"10.1016\/j.addr.2023.114819_b0790","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: Fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2023.114819_b0795","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrd2468","article-title":"Prodrugs: design and clinical applications","volume":"7","author":"Rautio","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2023.114819_b0800","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/jac\/dkl396","article-title":"Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus","volume":"58","author":"Warn","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2023.114819_b0805","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1358\/dot.2016.52.1.2404002","article-title":"Isavuconazonium sulfate for the treatment of fungal infection","volume":"52","author":"Walker","year":"2016","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.addr.2023.114819_b0810","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/jof6040239","article-title":"Fosmanogepix: A review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections","volume":"6","author":"Shaw","year":"2020","journal-title":"J. Fungi (Basel)"},{"key":"10.1016\/j.addr.2023.114819_b0815","doi-asserted-by":"crossref","first-page":"e02372","DOI":"10.1128\/AAC.02372-18","article-title":"APX001 pharmacokinetic\/pharmacodynamic target determination against Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis","volume":"63","author":"Zhao","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2023.114819_b0820","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1016\/j.bmcl.2003.08.029","article-title":"Phosphonooxymethyl prodrugs of the broad spectrum antifungal azole, ravuconazole: synthesis and biological properties","volume":"13","author":"Ueda","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.addr.2023.114819_b0825","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1128\/AAC.46.2.283-287.2002","article-title":"Efficacy of TAK-457, a novel intravenous triazole, against invasive pulmonary Aspergillosis in neutropenic mice","volume":"46","author":"Hayashi","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2023.114819_b0830","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1248\/cpb.49.1102","article-title":"Optically active antifungal azoles. XII. Synthesis and antifungal activity of the water-soluble prodrugs of 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H\u20131,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone","volume":"49","author":"Ichikawa","year":"2001","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.addr.2023.114819_b0835","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3390\/pharmaceutics13050633","article-title":"Antifungal activity of novel formulations based on terpenoid prodrugs against C. albicans in a mouse model","volume":"13","author":"Menon","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2023.114819_b0840","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1248\/cpb.58.794","article-title":"Design, synthesis and antifungal activity of the novel water-soluble prodrug of antifungal triazole CS-758","volume":"58","author":"Kagoshima","year":"2010","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.addr.2023.114819_b0845","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/0091270003262799","article-title":"Pharmacokinetics and safety of Fosfluconazole after single intravenous bolus injection in healthy male Japanese volunteers","volume":"44","author":"Sobue","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2023.114819_b0850","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2125.2004.02107.x","article-title":"Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers","volume":"58","author":"Sobue","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2023.114819_b0855","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00228-004-0764-x","article-title":"Comparison of the pharmacokinetics of fosfluconazole and fluconazole after single intravenous administration of fosfluconazole in healthy Japanese and Caucasian volunteers","volume":"60","author":"Sobue","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2023.114819_b0860","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/rcr2.49","article-title":"Pulmonary cryptococcosis presenting with a large cavity","volume":"2","author":"Morita","year":"2014","journal-title":"Respirol Case Rep."},{"key":"10.1016\/j.addr.2023.114819_b0865","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/dj7040102","article-title":"Pulmonary nodule in a patient with oral and lung cancer: Cryptococcus infection","volume":"7","author":"Yamagata","year":"2019","journal-title":"Dent. J. (Basel)"},{"key":"10.1016\/j.addr.2023.114819_b0870","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14787210.2015.990382","article-title":"Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases","volume":"13","author":"Seyedmousavi","year":"2015","journal-title":"Expert. Rev. Anti. Infect. Ther."},{"key":"10.1016\/j.addr.2023.114819_b0875","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1128\/JCM.00863-13","article-title":"In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds","volume":"51","author":"Pfaller","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.addr.2023.114819_b0880","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.cmi.2017.03.023","article-title":"Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates","volume":"23","author":"Astvad","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.addr.2023.114819_b0885","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/S0960-894X(02)00557-7","article-title":"Synthesis of novel water soluble benzylazolium prodrugs of lipophilic azole antifungals","volume":"12","author":"Ohwada","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.addr.2023.114819_b0890","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0960-894X(02)00892-2","article-title":"Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole","volume":"13","author":"Ohwada","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.addr.2023.114819_b0895","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s40265-016-0652-6","article-title":"Isavuconazole: A review in invasive aspergillosis and mucormycosis","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2023.114819_b0900","doi-asserted-by":"crossref","first-page":"126713","DOI":"10.1016\/j.bmcl.2019.126713","article-title":"Synthesis of analogs of the Gwt1 inhibitor manogepix (APX001A) and in vitro evaluation against Cryptococcus spp","volume":"29","author":"Trzoss","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.addr.2023.114819_b0905","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jgar.2021.04.012","article-title":"Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018\u20132019)","volume":"26","author":"Pfaller","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"10.1016\/j.addr.2023.114819_b0910","doi-asserted-by":"crossref","unstructured":"M.A. Pfaller, M.D. Huband, R.K. Flamm, P.A. Bien, M. Castanheira, In vitro activity of APX001A (Manogepix) and comparator agents against 1,706 fungal isolates collected during an international surveillance program in 2017, Antimicrob. Agents Chemother. 63 (2019) e00840-19.","DOI":"10.1128\/AAC.00840-19"},{"key":"10.1016\/j.addr.2023.114819_b0915","doi-asserted-by":"crossref","first-page":"e01735","DOI":"10.1128\/AAC.01735-19","article-title":"Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis","volume":"64","author":"Alkhazraji","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2023.114819_b0920","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1128\/AAC.00366-11","article-title":"Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis","volume":"55","author":"Hata","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2023.114819_b0925","doi-asserted-by":"crossref","first-page":"e02319","DOI":"10.1128\/AAC.02319-17","article-title":"In vitro and in vivo evaluation of the antifungal activity of APX001A\/APX001 against Candida auris","volume":"62","author":"Hager","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2023.114819_b0930","doi-asserted-by":"crossref","first-page":"e00523","DOI":"10.1128\/AAC.00523-18","article-title":"In vitro and in vivo evaluation of APX001A\/APX001 and other Gwt1 inhibitors against cryptococcus","volume":"62","author":"Shaw","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2023.114819_b0935","first-page":"e02542","article-title":"In vivo pharmacokinetics and pharmacodynamics of APX001 against Candida spp. in a neutropenic disseminated candidiasis mouse model","volume":"62","author":"Zhao","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2023.114819_b0940","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/s41564-022-01172-2","article-title":"COVID-19-associated fungal infections","volume":"7","author":"Hoenigl","year":"2022","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.addr.2023.114819_b0945","doi-asserted-by":"crossref","first-page":"919501","DOI":"10.3389\/fmicb.2022.919501","article-title":"COVID-19-associated fungal infections: An urgent need for alternative therapeutic approach?","volume":"13","author":"Doman","year":"2022","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2023.114819_b0950","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/cid\/ciab1070","article-title":"Investigational antifungal agents for invasive mycoses: A clinical perspective","volume":"75","author":"Lamoth","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2023.114819_b0955","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/jof6030122","article-title":"Review of the novel investigational antifungal olorofim","volume":"6","author":"Wiederhold","year":"2020","journal-title":"J. Fungi (Basel)"},{"key":"10.1016\/j.addr.2023.114819_b0960","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41586-019-1608-2","article-title":"The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL","volume":"574","author":"Aykut","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.114819_b0965","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1016\/j.cell.2022.09.013","article-title":"The tumor mycobiome: A paradigm shift in cancer pathogenesis","volume":"185","author":"Li","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.addr.2023.114819_b0970","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.biopha.2017.11.127","article-title":"Recent advances in delivery of antifungal agents for therapeutic management of candidiasis","volume":"96","author":"Sawant","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.addr.2023.114819_b0975","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijpharm.2017.03.019","article-title":"Nanoparticles as safe and effective delivery systems of antifungal agents: Achievements and challenges","volume":"523","author":"Soliman","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.114819_b0980","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2147\/JMDH.S359282","article-title":"Review on anomaterials and nano-scaled systems for topical and systemic delivery of antifungal drugs","volume":"15","author":"Nagasa","year":"2022","journal-title":"J. Multidiscip. Healthc."},{"key":"10.1016\/j.addr.2023.114819_b0985","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1021\/acs.molpharmaceut.0c01245","article-title":"Smart responsive quercetin-conjugated glycol chitosan prodrug micelles for treatment of inflammatory bowel diseases","volume":"18","author":"Shen","year":"2021","journal-title":"Mol. Pharm."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23001345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23001345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:31:40Z","timestamp":1759210300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X23001345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":197,"alternative-id":["S0169409X23001345"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2023.114819","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Target- and prodrug-based design for fungal diseases and cancer-associated fungal infections","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2023.114819","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114819"}}